著者
Jia GUAN Shiro TANAKA Shuhei YAMADA Izumi SATO Koji KAWAKAMI
出版者
Japanese Society for Pharmacoepidemiology
雑誌
薬剤疫学 (ISSN:13420445)
巻号頁・発行日
pp.25.e2, (Released:2020-07-15)
参考文献数
32
被引用文献数
1 2

Objective: To describe the treatment patterns and time to next treatment (TTNT) in newly diagnosed multiple myeloma patients (MM) using a large-scale claims database in Japan.Design: Cohort studyMethods: The patients with newly diagnosed MM from 2008 to 2015 were classified into two groups: age <65 years, and age ≥65 years. Specific regimens and general regimens were identified with a complex algorithm considering interval of no therapy, additional and discontinued agents. Correspondingly, TTNT between the first- and second-line were measured among non-transplant patients with Kaplan-Meier method.Results: A total of 425 patients were eligible to participate in the analysis. The most common regimen for the treatment of MM was bortezomib-based regimens (52.9% in the first-line, 28.2% in later lines), followed by melphalan-prednisolone (27.1% in the first-line, 12.9% in later lines) and lenalidomide-based regimens (4.7% in the first-line, 26.1% in later lines). TTNT between the first- and second-line was 11.4 months and was seen to vary greatly with each regimen. A statistically longer TTNT was observed in subgroups of patients aged 65 years or over compared with patients aged younger than 65 years, but no statistical difference was found between conventional therapy and novel therapy.Conclusion: Based on the data from the study, patients with MM were commonly treated with novel agent-based regimens, especially bortezomib-based regimens. Between the first- and second-line therapies a relatively short TTNT was observed, indicating that therapies in clinical practice poorly complied with treatment guidelines.

言及状況

外部データベース (DOI)

Twitter (3 users, 3 posts, 11 favorites)

@hommedefer3 レジメンの定義については私が知る限りはゴールドスタンダードがないので苦労するのですが、先行研究をレビューしたなかで最も納得感があり、かつ理解しやすかったのはこちらです。Figure1が参考になると思います。 https://t.co/vq0rdxt9qa

収集済み URL リスト